CPT® Code 86793

1. Indications

The antibody test for Yersinia (CPT® Code 86793) is indicated for the following conditions:

• Suspected Yersinia Infection The test is performed when a patient presents with symptoms suggestive of an infection caused by Yersinia, such as fever, abdominal pain, and swollen lymph nodes.
• Exposure History Individuals who have been in contact with confirmed cases of Yersinia infection or have been in areas where the bacteria are prevalent may be tested to determine if they have developed antibodies.
• Diagnostic Confirmation The test aids in confirming a diagnosis of bubonic plague or other Yersinia-related infections, particularly in patients exhibiting clinical signs consistent with these diseases.

2. Procedure

The procedure for testing antibodies to Yersinia involves several key steps:

• Sample Collection A healthcare professional collects a blood sample from the patient, typically via venipuncture. This process involves inserting a needle into a vein, usually in the arm, to draw a sufficient volume of blood for testing.
• Sample Preparation Once the blood sample is collected, it is processed in the laboratory. This may involve centrifugation to separate the serum from the blood cells, as the serum is required for the antibody testing.
• Testing Methodology The laboratory performs the antibody test using specific immunological techniques, such as enzyme-linked immunosorbent assay (ELISA) or indirect immunofluorescence, to detect the presence of antibodies against Yersinia in the serum sample.
• Result Interpretation After the testing is completed, the laboratory analyzes the results. A positive result indicates the presence of antibodies, suggesting a current or past infection with Yersinia, while a negative result suggests no detectable antibodies.

3. Post-Procedure

After the antibody test for Yersinia is performed, the patient may experience minimal discomfort at the site of blood collection, which typically resolves quickly. There are no specific post-procedure care instructions required for this test. However, patients should be informed about the potential for receiving results that may require further clinical evaluation or treatment based on the presence of antibodies. It is essential for healthcare providers to discuss the implications of the test results with the patient, including any necessary follow-up actions or additional testing that may be warranted based on the findings.